Dipeptidyl Peptidase 1 (DPP1) Inhibitor

Bronchiectasis is a chronic respiratory disease characterized by the permanent dilation of the bronchi and the destruction of bronchial wall structures. Non-Cystic Fibrosis Bronchiectasis (NCFBE) accounts for the vast majority of cases. Its etiology is diverse, including recurrent pulmonary infections, immunodeficiency, Chronic Obstructive Pulmonary Disease (COPD), asthma, Allergic Bronchopulmonary Aspergillosis (ABPA), and sequelae of tuberculosis. Clinical symptoms include chronic cough, purulent sputum production, dyspnea, and recurrent respiratory tract infections, which severely impact lung function and quality of life.

Current treatments for NCFBE primarily focus on symptom management—such as airway clearance, anti-infective therapy, and bronchodilators—or long-term antibiotic maintenance for patients with frequent exacerbations. There is a significant lack of specific anti-inflammatory therapies that target the underlying pathogenic mechanism to effectively interrupt the "vicious cycle" of the disease.

TG-4318: Breaking the Inflammatory Cycle at its Source A key pathological mechanism of NCFBE is the over-activation of Neutrophil Elastase (NE), which leads to continuous lung tissue destruction. Dipeptidyl Peptidase 1 (DPP1) is the essential enzyme responsible for activating multiple neutrophil serine proteases. As a highly potent DPP1 inhibitor, TG-4318 effectively blocks the activation pathway of NE, controlling bronchial inflammation at its source, reducing exacerbations and tissue damage, and ultimately improving pulmonary function.